Skip to content
Clinical Trials – home
Not yet recruiting

A Phase 3 Study of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy in Patients With Platinum‑Sensitive Recurrent Ovarian Cancer

Verified siteFast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The trial focuses on patients whose cancer has returned after initial chemotherapy and is still responsive to platinum‑based drugs. The cancers involved are a type of ovarian cancer called high‑grade serous ovarian cancer, as well as related cancers of the lining of the abdomen (primary peritoneal cancer) and the fallopian tubes. The investigational medicine is Raludotatug Deruxtecan, given through an intravenous infusion, and it may be combined with the antibody drug Bevacizumab. The purpose of the study is to determine whether this combination can keep the disease from progressing for a longer time than the usual standard treatment.

Participants who meet the study criteria will be assigned by chance to receive either the new drug alone, the new drug plus the antibody, or the current standard therapy. The assigned treatment is given by a drip into a vein every few weeks as a maintenance therapy, meaning it is used after the initial chemotherapy to try to prevent the cancer from coming back. The trial follows each participant for several months, with regular visits for safety checks, blood tests, and imaging scans to watch for any signs of disease growth. The study is open‑label, so the doctors and participants know which treatment is being given, and the overall design is a phase 3 trial, which is the final stage before a drug may be approved for general use.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and Assignment

    After joining the study, you will be randomly placed into one of two groups. One group receives raludotatug deruxtecan alone, and the other group receives raludotatug deruxtecan together with bevacizumab. Random assignment ensures that the comparison between treatments is fair.

  2. Step 2

    Start of Maintenance Therapy

    You will begin maintenance therapy, which means you will continue receiving medication to help keep the cancer from returning after initial treatment.

    The medication is given by intravenous infusion, a process where the drug is slowly delivered into a vein through a small needle.

    The dose of raludotatug deruxtecan is 4.8 mg per kilogram of your body weight.

    If you are in the combination group, you will also receive bevacizumab at a dose of 15 mg per kilogram of body weight.

  3. Step 3

    Regular Treatment Visits

    You will return to the clinic for each infusion according to the schedule defined by the study protocol.

    During each visit, the healthcare team will check your vital signs, review any side effects, and collect blood samples to monitor safety.

  4. Step 4

    Imaging and Disease Monitoring

    At specified intervals, you will undergo radiographic imaging (such as CT scans) to see whether the cancer shows any signs of growth.

    These images are examined by an independent committee to determine if the disease is progressing.

  5. Step 5

    Continuation Until Progression or Unacceptable Toxicity

    You will keep receiving the assigned infusion(s) until the study doctors decide that the cancer has progressed, you experience side effects that cannot be managed, or the study ends.

    At that point, treatment will be stopped and further care will be decided by your physician.

Who can join the trial?

13 criteria

  • Sign and date the Main Trial Screening informed consent form before any study procedures begin.
  • Have already received two separate courses of platinum‑based therapy (a type of chemotherapy that contains a platinum drug).
  • Show that the cancer has not gotten worse after the last platinum treatment, as proven by doctor‑reviewed scans using the RECIST 1.1 system (a way to measure tumor size) and a blood test called CA‑125 (a marker that can rise with ovarian‑type cancers).
  • Be ready to be randomly assigned to a treatment group between 4 and 9 weeks after the final dose of the platinum regimen.
  • Be willing and able to attend scheduled study visits, receive the study medication, have laboratory tests done, and follow any study restrictions.
  • Be at least 18 years old on the day you sign the consent form (or meet your country’s legal age requirement for research).
  • Be assigned female sex at birth.
  • Have a tissue diagnosis (by microscope examination) confirming high‑grade (Grade 3) serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian‑tube cancer.
  • Have a test result showing either HRD (homologous recombination deficiency) or a BRCA mutation, using a test that is approved or validated.
  • Have an ECOG performance status of 0 or 1 (meaning you are fully active or able to carry out light work).
  • Provide the required baseline laboratory results as specified by the study (such as blood counts and chemistry values).
  • According to the investigator, a drug called PARPi (a PARP inhibitor used as maintenance therapy) is not the preferred option for you as a second‑line treatment.
  • If you are a woman of child‑bearing potential, you must not be pregnant (confirmed by a sensitive pregnancy test), must not breast‑feed during the study and for at least 70 days after the last dose, and must use a highly effective, low‑maintenance form of contraception for the required time after each study drug (at least 8 months after R‑DXd, at least 6 months after bevacizumab). You also agree not to donate or freeze your eggs during this period.

Who cannot join the trial?

28 criteria

  • Having a tumor type that is not the specified high‑grade serous or endometrioid ovarian, fallopian‑tube, or peritoneal cancer (for example, germ‑cell tumors or low‑grade/borderline ovarian cancer). High‑grade serous means an aggressive form of ovarian cancer; low‑grade/borderline are less aggressive types.
  • Having ongoing side effects from previous cancer treatment that have not fully resolved (except hair loss), according to standard grading (grade 1 or higher). Grade measures how severe a side effect is.
  • Having a current bowel obstruction (including partial blockage), an abdominal fistula (abnormal connection), a gastrointestinal perforation (hole in the gut), or an intra‑abdominal abscess (collection of pus).
  • Having previously received drugs that target CDH6 or an antibody‑drug conjugate (ADC) that carries a topoisomerase I inhibitor (a type of chemotherapy).
  • Having a severe allergic reaction (grade 3 or higher) or any known reason not to use the study drug R‑DXd or its ingredients.
  • Having active or uncontrolled HIV infection that does not meet specific lab criteria (low CD4 count, detectable viral load, recent AIDS‑defining illness, or unstable HIV medication).
  • Having severe or uncontrolled other systemic diseases (such as active bleeding disorders, ongoing infection, or substance abuse) that would make participation unsafe or affect study compliance.
  • Having active or uncontrolled hepatitis B infection unless you are on antiviral therapy with an undetectable virus and normal liver enzymes (or only slightly elevated if liver metastases are present).
  • Having active or uncontrolled hepatitis C infection unless the virus is undetectable and liver enzymes are normal (or only slightly elevated if liver metastases are present).
  • Being pregnant, breastfeeding, or planning to become pregnant during the study.
  • Having personal or social circumstances (psychological, family, or travel issues) that would prevent regular follow‑up visits.
  • Not having enough time since major surgery, radiation, other cancer treatments, or certain medicines (e.g., chloroquine) – generally at least 28 days (or 14 days for some procedures) must have passed before starting the study.
  • Having any other illness, medical condition, recent surgery, physical finding, or lab abnormality that the doctor believes could affect safety, how the drug is processed in the body, or the study results.
  • Having received a live‑attenuated vaccine (a vaccine that contains a weakened live virus) within 30 days before the first dose of the study drug.
  • Having any contraindication (reason not to use) that is listed on the approved label for the standard control treatment.
  • If receiving bevacizumab (an anti‑VEGF drug): having a recent arterial clot event, serious bleeding, coughing up blood, or active gastrointestinal bleeding within the past 6 months (venous clots are allowed if well‑controlled).
  • Having a serious, non‑healing wound, active ulcer, or an untreated broken bone.
  • Having a history of abdominal fistula or gut perforation caused by prior VEGF‑targeted therapy.
  • Having stopped bevacizumab during the last platinum‑based chemotherapy because of side effects from bevacizumab.
  • Having a severe allergic reaction (grade 3 or higher) to bevacizumab or its ingredients, including sensitivity to certain cell‑derived products or human‑derived antibodies.
  • Having had major surgery, open biopsy, dental extraction, or other procedures that left an open wound, or a major injury (such as a long‑bone fracture requiring surgery) within 28 days before the first study dose, or needing such a procedure during the trial; also, placement of a vascular access device or core biopsy within 7 days is excluded.
  • Having active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis (cancer spread to the brain coverings) that are untreated, symptomatic, or require steroids or seizure medication.
  • Having had a stroke, mini‑stroke, or other arterial clot event within the past 6 months.
  • Having uncontrolled or serious heart disease (as defined by the study protocol).
  • Having any history of interstitial lung disease (ILD) or pneumonitis, current ILD, or imaging that suggests ILD that cannot be ruled out, unless it was radiation‑related pneumonitis that did not need steroids.
  • Having severe lung problems from other illnesses (e.g., recent pulmonary embolism, severe asthma, severe COPD, restrictive lung disease, large pleural fluid, or autoimmune diseases that affect the lungs) or having had a whole lung removed.
  • Taking chronic systemic steroids at a dose higher than 10 mg of prednisone (or equivalent) daily, except for certain inhaled, topical, or low‑dose uses listed.
  • Having another cancer (other than the ovarian, fallopian‑tube, or peritoneal cancer being studied) diagnosed within the past 3 years, unless it was a very low‑risk cancer that was treated curatively (e.g., early‑stage cervical cancer, non‑melanoma skin cancer, ductal carcinoma in situ, or stage 1 uterine cancer).
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Raludotatug Deruxtecan

    is an experimental medicine being tested in this study. It is given by an intravenous (IV) infusion, which means it is slowly dripped into a vein through a tube. In the trial, patients receive this drug after their cancer has responded to initial chemotherapy. The purpose of Raludotatug Deruxtecan is to try to keep the cancer from coming back and to extend the time patients live without their disease getting worse.

  • Bevacizumab

    is a well‑known antibody that blocks a protein called VEGF, which tumors use to grow new blood vessels. In this study, some participants receive bevacizumab together with Raludotatug Deruxtecan, while others receive Raludotatug Deruxtecan alone. It is also given by IV infusion. The goal of adding bevacizumab is to see whether blocking blood‑vessel growth can improve the ability of the experimental drug to keep the cancer under control.

What is already known about the treatment

  • Raludotatug Deruxtecan

    This medication is given as a solution for intravenous infusion. It is an investigational antibody‑drug conjugate that is still being studied in clinical trials and is not yet approved for general use. It is being tested as a maintenance treatment for platinum‑sensitive recurrent high‑grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer. It works by attaching a chemotherapy drug to an antibody that seeks out cancer cells, delivering the toxic payload directly to the tumor, and it is classified as an antibody‑drug conjugate (ADC).

  • Bevacizumab

    This medication is also administered as a solution for intravenous infusion. It is an approved monoclonal antibody that has been widely used in many cancers, including ovarian cancer, and is listed in medical literature as a standard therapy. It blocks a protein called VEGF, which stops new blood vessels from forming and therefore slows tumor growth. It belongs to the class of VEGF inhibitors, a type of anti‑angiogenic therapy.

Investigated diseases

Platinum‑sensitive high‑grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer - This disease is a group of cancers that arise from the lining of the ovary, the peritoneum, or the fallopian tube. They are classified as high‑grade serous or endometrioid based on cell appearance, and they usually respond to platinum‑based chemotherapy, defining them as platinum‑sensitive when the cancer returns after at least six months. Over time the tumors can grow on the surface of the abdominal cavity and may spread to nearby organs. As the disease progresses, patients may notice increasing abdominal swelling, pain, or changes in bowel habits. The cancer can continue to enlarge and form new nodules, leading to further involvement of the peritoneal lining. The pattern of growth typically follows a stepwise spread within the abdomen.
Trial detailsLast updated 15 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2025-522715-41-00Protocol codeDS6000-169Estimated enrolment409 patientsSponsorDaiichi Sankyo Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.